Clots and cancer

Bibliography

• 1  Kakkar AK, Williamson RC: Antithrombotic therapy in cancer. Br. Med. J.318(7198),1571–1572 (1999).Crossref, Medline, CAS, Google Scholar
• 2  Kakkar AK, Levine MN, Kadziola Z et al.: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol.22(10),1944–1948 (2004).Crossref, Medline, CAS, Google Scholar
• 3  Lee AY, Levine MN, Baker RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349(2),146–153 (2003).Crossref, Medline, CAS, Google Scholar
• 4  Altinbas M, Coskun HS, Er O et al.: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost.2(8),1266–1271 (2004).Crossref, Medline, CAS, Google Scholar
• 5  Klerk CP, Smorenburg SM, Otten HM et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol.23(10),2130–2135 (2005).Crossref, Medline, CAS, Google Scholar
• 6  Lee AY, Rickles FR, Julian JA et al.: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol.23(10),2123–2129 (2005).Crossref, Medline, CAS, Google Scholar
• 7  Kakkar AK, Levine MN: Thrombosis and cancer: implications beyond Trousseau. J. Thromb. Haemost.2(8),1261–1262 (2004).Crossref, Medline, CAS, Google Scholar
• 8  Ferretti G, Bria E, Giannarelli D et al.: Does low-molecular-weight heparin influence cancer-related mortality? Ann. Oncol.17(10),1604–1606 (2006).Crossref, Medline, CAS, Google Scholar
• 9  Kakkar AK: Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control12(Suppl. 1),22–30 (2005).Crossref, Medline, Google Scholar
• 10  Bick RL: Cancer-associated thrombosis. N. Engl. J. Med.349(2),109–111 (2003).Crossref, Medline, CAS, Google Scholar
• 11  Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR: Control of angiogenesis with synthetic heparin substitutes. Science243(4897),1490–1493 (1989).Crossref, Medline, CAS, Google Scholar
• 12  Nasir FA, Patel HK, Scully MF et al.: The low molecular weight heparin inhibits angiogenesis and induces apoptosis in an experimental tumour model. Blood102(11) Abstract (2003).Google Scholar
• 13  Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD: Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J. Thromb. Haemost.2(12),2107–2114 (2004).Crossref, Medline, CAS, Google Scholar
• 14  Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N. Engl. J. Med.342(26),1953–1958 (2000).Crossref, Medline, CAS, Google Scholar